This trial is evaluating whether 64Cu-DOTA-ECLIi will improve 4 primary outcomes in patients with Pancreatic Adenocarcinoma (Ductal Adenocarcinoma). Measurement will happen over the course of Completion of first scan (day 1).
This trial requires 75 total participants across 3 different treatment groups
This trial involves 3 different treatments. 64Cu-DOTA-ECLIi is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Pancreatic ductal adenocarcinomas are treated by major surgical techniques such as distal pancreatectomy, local surgery, and neoadjuvant chemotherapy in selected patients. New surgical techniques such as subserosal dissection and robot-assisted hepaticoduodenectomy might be more efficient in selected patients." - Anonymous Online Contributor
"It appears that this condition is not just a single entity, but a group of conditions which are caused, or worsened, by a variety of different factors. For most ductal adenocarcinoma patients, the cancer appears to have formed for a long time. Many patients with ductal adenocarcinoma develop the condition as a result of a previous history of other cancers, including liver and colon, and in less common circumstances there may be a link between genetics, toxins, and other environmental insults." - Anonymous Online Contributor
"A palpable abdominal mass is present in approximately 20% of patients with pancreatic cancer. Other signs include anemia, abdominal pain, jaundice, and weight loss. This article outlines the signs of pancreatic adenocarcinoma." - Anonymous Online Contributor
"Around 25,000 people get pancreatic adenocarcinoma a year in the United States. This is the third most common cancer (after colorectal cancer and breast cancer) in American men." - Anonymous Online Contributor
"Pancreatic ductal adenocarcinoma is commonly associated with a poor prognosis. However, surgery and chemotherapy are highly effective and a cure can be achieved with long-term follow-up." - Anonymous Online Contributor
"Pancreatic adenocarcinoma (ductal adenocarcinoma), also known as adenocarcinoma of the pancreas. It is a form of adenocarcinoma of the pancreas whose malignant cells originate from the pancreas. The malignant cells of pancreatic adenocarcinoma are capable of spreading and producing more malignant cells, metastasizing, and eventually forming an aggressive tumor.\n" - Anonymous Online Contributor
"There are more than one million treatments annually for [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) in Ontario. Of these, approximately 45,000 involve chemotherapy and over 5% involve 64Cu-DOTA-eclii. No clinical trial was found concerning 64Cu-DOTA-eclii treatment of patients with colorectal cancer. Until there is a better understanding of colorectal cancer, our present knowledge of therapy for cancer is largely based on research done using other modes of imaging. Clinical trials in this area are needed." - Anonymous Online Contributor
"This is the first study to produce a complete analysis of age at the time of diagnosis for pd-pCRM. Results from a recent paper of this study demonstrate that there is no consensus among surgeons or pathologists, whether or not pd-pCRM should be regarded as a "serous" or a non-serous tumor. This fact, and the lack of the consensus as to "serous" versus non-serous pd-pCRM, is probably the most important reason why pd-pCRM behaves differently than previously thought. The data also show that p-PD-pCRM is a disease of the very old." - Anonymous Online Contributor
"Because this is a rare disease, the only patients that can benefit from clinical trials should likely be those with a poor prognosis, or those that prefer curative treatment, regardless of trial outcomes." - Anonymous Online Contributor
"The majority of the 64Cu-dota-eclii treatment centers in Germany have shifted from ECLIT alone to BEACT-2, the BEACH-2/EART trial comparing ECLIT with standard chemoimmunotherapy. In many studies, the chemotherapy-related death rate is now markedly reduced in BEACT-2 compared to ECLIT. In the following years, more chemotherapy regimens, in particular the TACE approach, will be investigated further, which might result in more efficient treatment, which can result in much improved survival rates in advanced stages of carcinoma of the pancreas." - Anonymous Online Contributor
"Results from a recent clinical trial has demonstrated that 64Cu-dota-eclii, a single radioembolization treatment of pancreatic adenocarcinoma, is an effective treatment. It is associated with low rates of serious toxicities, and allows for the administration of systemic therapy for patients with unresectable pancreatic adenocarcinoma, by a procedure that is easy and safe for patients to undergo. Therefore, 64Cu-dota-eclii should be investigated for further investigations." - Anonymous Online Contributor
"The treatment of pancreatic cancer in the 21st century is mainly centered on the use of newer technologies and more efficient drugs. The survival rate for pancreatic cancer patients in developed countries has improved considerably recently. However, the median survival period remains in the 1- to 2-year range when compared to the previous decades. There is an urgent need to find a more effective treatment approach for pancreatic cancer. The development of more effective treatments for pancreatic cancer is a goal that deserves our attention and it will benefit all individuals with this rare tumor." - Anonymous Online Contributor